



- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *A61K 39/00* (2006.01)
- (21) **International Application Number:**
PCT/EP2015/074178
- (22) **International Filing Date:**
19 October 2015 (19.10.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
14189374.3 17 October 2014 (17.10.2014) EP
- (71) **Applicant:** GLENMARK PHARMACEUTICALS S.A.
[CH/CH]; Chemin de la Combeta 5, CH-2300 La Chaux-
de-Fonds (CH).
- (72) **Inventors:** LISSILAA, Rami; c/o Glenmark Pharmaceut-
icals S.A., Chemin de la Combeta 5, CH-2300 La Chaux-
de-Fonds (CH). WALMSLEY, Adrian; c/o Glenmark
Pharmaceuticals S.A., Chemin de la Combeta 5, CH-2300
La Chaux-de-Fonds (CH). BLEIN, Stanislas; c/o Glen-
mark Pharmaceuticals S.A., Chemin de la Combeta 5, CH-
2300 La Chaux-de-Fonds (CH). OLLIER, Romain; c/o
Glenmark Pharmaceuticals S.A., Chemin de la Combeta 5,
CH-2300 La Chaux-de-Fonds (CH). HOU, Samuel;
Chemin de la Combeta 5, CH-2300 La Chaux-de-Fonds
(CH). LOYAU, Jeremy; c/o Glenmark Pharmaceuticals
S.A., Chemin de la Combeta 5, CH-2300 La-Chaux-de-
Fonds (CH).
- (74) **Agent:** SCHOELLHORN, Andreas; Latscha Schöllhorn
Partner AG, Austrasse 24, CH-4051 Basel (CH).

- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

- with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(54) **Title:** ANTIBODIES THAT BIND TO CCR6 AND THEIR USES

(57) **Abstract:** The present invention relates to antibodies or fragments thereof that bind to CCR6. More specifically, the present invention relates to an antibody or fragment thereof that binds to CCR6 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 31, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 32, SEQ ID NO: 190, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 254 or SEQ ID NO: 255 and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 33; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 34, SEQ ID NO: 191, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246 or SEQ ID NO: 256, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 35, SEQ ID NO: 247, SEQ ID NO: 248 or SEQ ID NO: 257 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 36 or SEQ ID NO: 192 or SEQ ID NO: 193.

